At its first meeting under the new administration, the US Centers for Disease Control and Prevention’s (CDC) Advisory ...

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in ...

A CDC committee has voted to expand its respiratory syncytial virus vaccine recommendation to include all people aged 50 to ...

The study authors say the findings highlight the complex and multifaceted nature of antibiotic resistance in group B strep.

On Wednesday, the Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of ...

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

Among the 25% of participants in 1 study who said they experienced long-COVID symptoms, 13% reported sleep disorders.

A panel of federal health experts on Wednesday recommended expanded vaccine options for several diseases, including ...

A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...

Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...

The CDC’s Advisory Committee on Immunization Practices voted April 16 to expand use of respiratory syncytial virus vaccines among high-risk adults. The updated recommendation calls for a single ...